Skip to main content
. 2024 May 27;25(11):5817. doi: 10.3390/ijms25115817

Figure 4.

Figure 4

Percentage of IBD patients with a positive (+) and negative (−) C-reactive protein (CRP) test at baseline (n = 17) and after 24 weeks (n = 17) and 52 weeks (n = 11) of treatment with vedolizumab (VDZ). Numbers in the bars are the number of subjects included. The Fisher exact test was used for comparisons. ** p < 0.01 and *** p < 0.001 vs. IBD baseline.